ReviewJournal of mammary gland biology and neoplasia1997
Roles of ErbB-3 and ErbB-4 in the physiology and pathology of the mammary gland.
Review in Journal of mammary gland biology and neoplasia, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 35 citations in OpenAlex.
- Multiomics of HER2-low triple-negative breast cancer identifies a receptor tyrosine kinase-relevant subgroup with therapeutic prospects.JCI insight · 2023Article
- The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.Pharmacological reviews · 2022Review
- Transmembrane Mucins: Signaling Receptors at the Intersection of Inflammation and Cancer.Journal of innate immunity · 2017Review
- Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status.Cancer medicine · 2015Article
- Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.Oncotarget · 2014Article
- Amplification and deletion of the RAPH1 gene in breast cancer patients.Molecular biology reports · 2013Article
- Vertebrate Lrig3-ErbB interactions occur in vitro but are unlikely to play a role in Lrig3-dependent inner ear morphogenesis.PloS one · 2010Article
- Gamma-heregulin has no biological significance in primary breast cancer.British journal of cancer · 2002Article
- The ErbB receptors as targets for breast cancer therapy.Journal of mammary gland biology and neoplasia · 1999Review
- Complete sequence of the human mucin MUC4: a putative cell membrane-associated mucin.The Biochemical journal · 1999Article
- Sialomucin complex at the rat ocular surface: a new model for ocular surface protection.The Biochemical journal · 1998Article
- Sialomucin complex in the rat respiratory tract: a model for its role in epithelial protection.The Biochemical journal · 1998Article
- Hormonal regulation of type I receptor tyrosine kinase expression in the mammary gland.Journal of mammary gland biology and neoplasia · 1997Review
- EGF-related peptides and their receptors in mammary gland development.Journal of mammary gland biology and neoplasia · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
ErbB-3 and ErbB-4 are the most recently discovered and least characterized of the class I tyrosine kinase receptors. ErbB-3 is noteworthy for its low tyrosine kinase activity, suggesting that it may function more as an adaptor in signaling than as a kinase. Heregulin serves as a ligand for both receptors. A primary mechanism of heregulin action involves heterodimerization of its targeted receptors with other members of the class I family to promote cross-phosphorylation and cellular responses. Betacellulin also acts as a ligand for ErbB-4 to stimulate its kinase activity in both homo- and hetero-dimers. A new ligand (ASGP-2) for ErbB-2 has been discovered which operates by an intramembrane mechanism and may be able to modulate external ligand-dependent ErbB-3 or ErbB-4 heterodimeric interactions with ErbB-2. Heterodimerization stimulated by the ligands is a key feature of mitogenic signaling in mammary epithelial cells and tumors. Characterization of the signaling pathways for these receptors is still incomplete, but phosphatidylinositol 3-kinase and SHC have been implicated. Heregulin synthesized by the mesenchyme has been implicated in mammary development, modulated by systemic hormones. Observations on cultured mammary cells and mammary tumors have suggested linkages of ErbB-3 and ErbB-4 to proliferation and differentiation, respectively, but further work is needed to establish their definitive roles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.